Dotarem and Memory loss - a phase IV clinical study of FDA data

Summary:

Memory loss is reported as a side effect among people who take Dotarem (gadoterate meglumine), especially for people who are female, 40-49 old, have been taking the drug for < 1 month also take Magnevist, and have Nuclear magnetic resonance imaging brain.

The phase IV clinical study analyzes which people have Memory loss when taking Dotarem. It is created by eHealthMe based on reports of 2,749 people who have side effects when taking Dotarem from the FDA, and is updated regularly.

What is Dotarem?

Dotarem has active ingredients of gadoterate meglumine. eHealthMe is studying from 2,749 Dotarem users. Check the latest studies of Dotarem.

What is Memory loss?

Memory loss is found to be associated with 2,729 drugs and 4,375 conditions by eHealthMe. Check the latest studies of Memory loss.

On Jul, 10, 2026

2,749 people reported to have side effects when taking Dotarem.
Among them, 40 people (1.46%) have Memory loss.

Among these 40 people:

How long have people been on Dotarem when they have Memory loss? *

What is the gender of people who have Memory loss when taking Dotarem? *

female: 64.1 %
male: 35.9 %

What is the age of people who have Memory loss when taking Dotarem? *

What are other drugs people take besides Dotarem? *

What are other side effects people have besides Memory loss? *

Disturbance In Attention: 21 people, 52.50%
Weakness: 18 people, 45.00%
Headache (pain in head): 17 people, 42.50%
Muscle Twitching: 17 people, 42.50%
Fatigue (feeling of tiredness): 14 people, 35.00%
Itching: 12 people, 30.00%
Dizziness: 11 people, 27.50%
Joint Pain: 11 people, 27.50%
Visual Impairment: 11 people, 27.50%
Tremor (trembling or shaking movements in one or more parts of your body): 10 people, 25.00%

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 5 people, 12.50%
Sarcoidosis (an inflammatory disease that affects multiple organs in the body, but mostly the lungs and lymph glands): 3 people, 7.50%
Nuclear Magnetic Resonance Imaging Abdominal: 3 people, 7.50%
Neurosarcoidosis (a condition of unknown cause featuring a collection of immune cells in various tissues, involving the central nervous system (brain and spinal cord)): 3 people, 7.50%
Prostate Cancer: 2 people, 5.00%
Pain: 2 people, 5.00%
Gigantism (excessive growth and height): 2 people, 5.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 5.00%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 2 people, 5.00%
Urinary Tract Disorder: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Dotarem and have Memory loss?

- Check whether Memory loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Dotarem:

Dotarem (2,749 reports)

Memory loss treatments and more:

Memory loss (244,444 reports)

Browse all side effects of Dotarem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Memory loss:

Memory loss (2,729 drugs)

Browse all the conditions that are associated with Memory loss:

Memory loss (4,375 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gadoterate meglumine (the active ingredients of Dotarem) and Dotarem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.